OKYO vs. TVGN, OCGN, ANNX, MDWD, CRDF, FHTX, URGN, SLRN, CGC, and GNFT
Should you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include Tevogen Bio (TVGN), Ocugen (OCGN), Annexon (ANNX), MediWound (MDWD), Cardiff Oncology (CRDF), Foghorn Therapeutics (FHTX), UroGen Pharma (URGN), Acelyrin (SLRN), Canopy Growth (CGC), and Genfit (GNFT). These companies are all part of the "pharmaceutical products" industry.
OKYO Pharma vs. Its Competitors
Tevogen Bio (NASDAQ:TVGN) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, community ranking, dividends, analyst recommendations, institutional ownership, earnings and risk.
3.0% of OKYO Pharma shares are held by institutional investors. 73.2% of Tevogen Bio shares are held by company insiders. Comparatively, 40.5% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
OKYO Pharma's return on equity of 0.00% beat Tevogen Bio's return on equity.
In the previous week, Tevogen Bio had 7 more articles in the media than OKYO Pharma. MarketBeat recorded 10 mentions for Tevogen Bio and 3 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 0.62 beat Tevogen Bio's score of 0.58 indicating that OKYO Pharma is being referred to more favorably in the news media.
OKYO Pharma received 3 more outperform votes than Tevogen Bio when rated by MarketBeat users.
Tevogen Bio has a beta of -0.69, suggesting that its share price is 169% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.27, suggesting that its share price is 127% less volatile than the S&P 500.
Tevogen Bio currently has a consensus target price of $7.10, suggesting a potential upside of 459.06%. OKYO Pharma has a consensus target price of $7.00, suggesting a potential upside of 176.68%. Given Tevogen Bio's higher possible upside, equities analysts clearly believe Tevogen Bio is more favorable than OKYO Pharma.
Summary
Tevogen Bio beats OKYO Pharma on 6 of the 11 factors compared between the two stocks.
Get OKYO Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OKYO Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:OKYO) was last updated on 6/13/2025 by MarketBeat.com Staff
